Pathophysiological mechanisms regulated by cytokines in gliomas

Cytokine

Volumn 71, Issue 2, 2015, Pages 377-384

  Christofides, Anthos ^a   Kosmopoulos, Marinos ^a   Piperi, Christina ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cytokines; Glioma; IL 18; TGF ; TNF

Indexed keywords

CANCER VACCINE; CHEMOKINE; CYTOKINE; DOXORUBICIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TRABEDERSEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; BIOLOGICAL MARKER; INTERLEUKIN 18;

APOPTOSIS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; GENETIC REGULATION; GLIOMA; HUMAN; IMMUNOMODULATION; MOLECULAR PATHOLOGY; REVIEW; ANIMAL; BRAIN TUMOR; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC EPIGENESIS; METABOLISM; MICROGLIA; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CYTOKINES; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; GLIOMA; HUMANS; INTERLEUKIN-18; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; MICROGLIA; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84921279002     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.09.008     Document Type: Review

References (104)

1. Sciumè G., Santoni A., Bernardini G. Chemokines and glioma: invasion and more. J Neuroimmunol 2010, 224:8-12.
2. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee Burger P.C., Jouvet A., Scheithauer B.W., et al. WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 2007(114):97-109.
3. Brantley E.C., Benveniste E.N. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 2008, 6:675-684.
4. Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav Immun 2003, 17:13-19.
5. Carta S., Lavieri R., Rubartelli A. Different members of the IL-1 family come out in different ways: DAMPs vs. cytokines?. Front Immunol 2013, 4:123.
6. Szelényi J. Cytokines and the central nervous system. Brain Res Bull 2001, 54:329-338.
7. Stolp H.B. Neuropoietic cytokines in normal brain development and neurodevelopmental disorders. Mol Cell Neurosci 2013, 53:63-68.
8. Bialas A.R., Stevens B. Glia: regulating synaptogenesis from multiple directions. Curr Biol 2012, 22:R833-5.
9. Bilbo S.D., Schwarz J.M. Early-life programming of later-life brain and behavior: a critical role for the immune system. Front Behav Neurosci 2009, 3:14.
10. Patterson P.H. Cytokines and the function of the mature nervous system. C R Acad Sci 1993, III(316):1141-1157.
11. Bastien D., Lacroix S. Cytokine pathways regulating glial and leukocyte function after spinal cord and peripheral nerve injury. Exp Neurol 2014, 258:62-77.
12. Pajer K., Feichtinger G.A., Márton G., Sabitzer S., Klein D., Redl H., et al. Cytokine signaling by grafted neuroectodermal stem cells rescues motoneurons destined to die. Exp Neurol 2014, 261C:180-189.
13. Palazuelos J., Klingener M., Aguirre A. TGFβ signaling regulates the timing of CNS myelination by modulating oligodendrocyte progenitor cell cycle exit through SMAD3/4/FoxO1/Sp1. J Neurosci 2014, 34(23):7917-7930.
14. Colton C.A., Wilcock D.M. Assessing activation states in microglia. CNS Neurol Disord Drug Targets 2010, 9(2):174-191.
15. Yeung Y.T., McDonald K.L., Grewal T., Munoz L. Interleukins in glioblastoma pathophysiology: implications for therapy. Br J Pharmacol 2013, 168(3):591-606.
16. Platten M., Wick W., Weller M. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 2001, 52:401-410.
17. Abreu J.G., Ketpura N.I., Reversade B., De Robertis E.M. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002, 4:599-604.
18. Song H., Stevens C.F., Gage F.H. Astroglia induce neurogenesis from adult neural stem cells. Nature 2002, 417:39-44.
19. Ullian E.M., Sapperstein S.K., Christopherson K.S., Barres B.A. Control of synapse number by glia. Science 2001, 291:657-661.
20. Gomes F.C., Sousa Vde O., Romão L. Emerging roles for TGF-beta1 in nervous system development. Int J Dev Neurosci 2005, 23:413-424.
21. Nadarajah B., Parnavelas J.G. Modes of neuronal migration in the developing cerebral cortex. Nat Rev Neurosci 2002, 3:423-432.
22. Martinez R., Gomes F.C. Neuritogenesis induced by thyroid hormone-treated astrocytes is mediated by epidermal growth factor/mitogen-activated protein kinase-phosphatidylinositol 3-kinase pathways and involves modulation of extracellular matrix proteins. J Biol Chem 2002, 277:49311-49318.
23. Schneider T., Sailer M., Ansorge S., Firsching R., Reinhold D. Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol 2006, 79:61-65.
24. Yang L., Liu M., Deng C., Gu Z., Gao Y. Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma. Tumour Biol 2012, 33:1477-1484.
25. Zonis S., Ljubimov V.A., Mahgerefteh M., Pechnick R.N., Wawrowsky K., Chesnokova V. P21(Cip) restrains hippocampal neurogenesis and protects neuronal progenitors from apoptosis during acute systemic inflammation. Hippocampus 2013, 23:1383-1394.
26. Seoane J., Le H.V., Shen L., Anderson S.A., Massagué J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004, 117:211-223.
27. Nickl-Jockschat T., Arslan F., Doerfelt A., Bogdahn U., Bosserhoff A., Hau P. An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas. Int J Oncol 2007, 30:499-507.
28. Yamada N., Kato M., Yamashita H., Nistér M., Miyazono K., Heldin C.H., et al. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 1995, 62:386-392.
29. Dhandapani K.M., Khan M.M., Wade F.M., Wakade C., Mahesh V.B., Brann D.W. Induction of transforming growth factor-beta1 by basic fibroblast growth factor in rat C6 glioma cells and astrocytes is mediated by MEK/ERK signaling and AP-1 activation. J Neurosci Res 2007, 85:1033-1045.
30. Platten M., Wick W., Wild-Bode C., Aulwurm S., Dichgans J., Weller M. Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. Biochem Biophys Res Commun 2000, 268:607-611.
31. Crane C.A., Han S.J., Barry J.J., Ahn B.J., Lanier L.L., Parsa A.T. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol 2010, 12:7-13.
32. Wang L., Liu Z., Balivada S., Shrestha T., Bossmann S., Pyle M., et al. Interleukin-1β and transforming growth factor-β cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells. Stem Cell Res Ther 2012, 3:5.
33. Wallace P.K., Romet-Lemonne J.L., Chokri M., Kasper L.H., Fanger M.W., Fadul C.E. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor. Cancer Immunol Immunother 2000, 49:493-503.
34. Yeh W.L., Lu D.Y., Liou H.C., Fu W.M. A forward loop between glioma and microglia: glioma-derived extracellular matrix-activated microglia secrete IL-18 to enhance the migration of glioma cells. J Cell Physiol 2012, 227:558-568.
35. Suk K., Yeou Kim S., Kim H. Regulation of IL-18 production by IFN gamma and PGE2 in mouse microglial cells: involvement of NF-kB pathway in the regulatory processes. Immunol Lett 2011, 77:79-85.
36. Yamanaka R., Honma J., Tsuchiya N., Yajima N., Kobayashi T., Tanaka R. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. J Neurooncol 2005, 72:107-113.
37. Woo J.S., Kim S.M., Jeong C.H., Ryu C.H., Jeun S.S. Lipoxygenase inhibitor MK886 potentiates TRAIL-induced apoptosis through CHOP- and p38 MAPK-mediated up-regulation of death receptor 5 in malignant glioma. Biochem Biophys Res Commun 2013, 431:354-359.
38. Kahana S., Finniss S., Cazacu S., Xiang C., Lee H.K., Brodie S., et al. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions. Cell Signal 2011, 23:1348-1357.
39. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195.
40. Xiao C., Yang B.F., Asadi N., Beguinot F., Hao C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 2002, 277:25020-25025.
41. Kim E.H., Kim S., Shin D., Choi K.S. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004, 23:446-456.
42. Kim E.H., Kim H.S., Kim S., Noh E.J., Lee J.S., Choi K.S. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 2005, 24:6877-6889.
43. Kim E.H., Kim S., Choi K.S. Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 2005, 24:838-849.
44. Lee D.H., Kim D.W., Jung C.H., Lee Y., Park D. Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells. Toxicol Appl Pharmacol 2014, 279:253-265.
45. Calzolari A., Saulle E., De Angelis M.L., Pasquini L., Boe A., Pelacchi F., et al. Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines. PLoS ONE 2014, 9:e94438.
46. Dorsey J., Mintz A., Tian X. Tumor necrosis factor-related apoptosis-inducing ligand, (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol Cancer Ther 2009, 8:3285-3295.
47. Allen J. Translocation, Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects. Sci Transl Med 2013, 5:171ra17.
48. Yoon M.J., Kang Y.J., Kim I.Y., Kim E.H., Lee J.A., Lim J.H., et al. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis 2013, 34:1918-1928.
49. Deshayes F., Laprée G., Portier A., Richard Y., Pencalet P., Mahieu-Caputo D., et al. Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene 2004, 23:3005-3012.
50. do Carmo A., Balça-Silva J., Matias D., Lopes M.C. PKC signaling in glioblastoma. Cancer Biol Ther 2013, 14:287-294.
51. Samaras V., Piperi C., Levidou G., Zisakis A., Kavantzas N., Themistocleous M.S., et al. Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum Immunol 2009, 70:391-397.
52. Brat D.J., Bellail A.C., Van Meir E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 2005, 7:122-133.
53. Gabellini C., Castellini L., Trisciuoglio D., Kracht M., Zupi G., Del Bufalo D. Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma. J Neurochem 2008, 107:871-882.
54. Choi C., Kutsch O., Park J., Zhou T., Seol D.W., Benveniste E.N. Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells. Mol Cell Biol 2002, 22:724-736.
55. Yao M., Zhou R.H., Petreaca M., Zheng L., Shyy J., Martins-Green M. Activation of sterol regulatory element-binding proteins (SREBPs) is critical in IL-8-induced angiogenesis. J Leukoc Biol 2006, 80:608-620.
56. Li A., Dubey S., Varney M.L., Dave B.J., Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170:3369-3376.
57. Sharma V., Dixit D., Koul N., Mehta V.S., Sen E. Ras regulates interleukin-1β-induced HIF-1α transcriptional activity in glioblastoma. J Mol Med (Berl) 2011, 89:123-136.
58. Kaluz S., Van Meir E.G. At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loop. J Mol Med (Berl) 2011, 89:91-94.
59. Kim Y.J., Hwang S.Y., Oh E.S., Oh S., Han I.O. IL-1beta, an immediate early protein secreted by activated microglia, induces iNOS/NO in C6 astrocytoma cells through p38 MAPK and NF-kappaB pathways. J Neurosci Res 2006, 84:1037-1046.
60. Xu W., Liu L.Z., Loizidou M., Ahmed M., Charles I.G. The role of nitric oxide in cancer. Cell Res 2002, 12:311-320.
61. Zheng W., Li Z., Jia J., An J. Establishment of nestin transgenic mice and nestin expression in the organs. Nan Fang Yi Ke Da Xue Xue Bao 2013, 33:1155-1159.
62. Jin X., Jin X., Jung J.E., Beck S., Kim H. Cell surface nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun 2013, 433:496-501.
63. Bryan L., Paugh B.S., Kapitonov D., Wilczynska K.M., Alvarez S.M., Singh S.K., et al. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness. Mol Cancer Res 2008, 6:1469-1477.
64. Chang C.Y., Li M.C., Liao S.L., Huang Y.L., Shen C.C., Pan H.C. Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci 2005, 12:930-933.
65. Tchirkov A., Khalil T., Chautard E., Mokhtari K., Véronèse L., Irthum B., et al. Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 2007, 96:474-476.
66. Saidi A., Hagedorn M., Allain N., Verpelli C., Sala C., Bello L., et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer 2009, 125:1054-1064.
67. Loeffler S., Fayard B., Weis J., Weissenberger J. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 2005, 115:202-213.
68. Shu M., Zhou Y., Zhu W., Wu S., Zheng X., Yan G. Activation of a pro-survival pathway IL-6/JAK2/STAT3 contributes to glial fibrillary acidic protein induction during the cholera toxin-induced differentiation of C6 malignant glioma cells. Mol Oncol 2011, 5:265-272.
69. Sparacio S.M., Zhang Y., Vilcek J., Benveniste E.N. Cytokine regulation of interleukin-6 gene expression in astrocytes involves activation of an NF-kappa B-like nuclear protein. J Neuroimmunol 1992, 39:231-242.
70. Qiu B., Zhang D., Wang Y., Ou S., Wang J., Tao J., et al. Interleukin-6 is overexpressed and augments invasiveness of human glioma stem cells in vitro. Clin Exp Metastasis 2013, 30:1009-1018.
71. Wang H., Lathia J.D., Wu Q., Wang J., Li Z., Heddleston J.M., et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009, 27:2393-2404.
72. Jin X., Kim S.H., Jeon H.M., Beck S., Sohn Y.W., Yin J., et al. Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling. Brain 2012, 135:1055-1069.
73. Qiu B., Zhang D., Wang C., Tao J., Tie X., Qiao Y., et al. IL-10 and TGF-β2 are overexpressed in tumor spheres cultured from human gliomas. Mol Biol Rep 2011, 38:3585-3591.
74. Zhang L., Handel M.V., Schartner J.M., Hagar A., Allen G., Curet M., et al. Regulation of IL-10 expression by upstream stimulating factor (USF-1) in glioma-associated microglia. J Neuroimmunol 2007, 184:188-197.
75. Akasaki Y., Liu G., Chung N.H., Ehtesham M., Black K.L., Yu J.S. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 2004, 173:4352-4359.
76. Paladugu M., Thakur A., Lum L.G., Mittal S., Parajuli P. Generation and immunologic functions of Th17 cells in malignant gliomas. Cancer Immunol Immunother 2013, 62:75-86.
77. De Vleeschouwer S., Spencer Lopes I., Ceuppens J.L., Van Gool S.W. Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells. J Neurooncol 2007, 84:131-140.
78. Domanska U.M., Kruizinga R.C., den Dunnen W.F., Timmer-Bosscha H., de Vries E.G., Walenkamp A.M. The chemokine network, a newly discovered target in high grade gliomas. Crit Rev Oncol Hematol 2011, 79:154-163.
79. International Union of Immunological Societies/World Health Organization Subcommittee on chemokine nomenclature Chemokine/chemokine receptor nomenclature. J Leukoc Biol 2001, 70:465-466.
80. Lazarini F., Tham T.N., Casanova P., Arenzana-Seisdedos F., Dubois-Dalcq M. Role of the alpha-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system. Glia 2003, 42:139-148.
81. Bajetto A., Bonavia R., Barbero S., Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 2002, 82:1311-1329.
82. Zlotnik A. Chemokines and cancer. Int J Cancer 2006, 119:2026-2029.
83. Calatozzolo C., Maderna E., Pollo B., Gelati M., Marras C., Silvani A., et al. Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biol Ther 2006, 5:827-832.
84. Rempel S.A., Dudas S., Ge S., Gutiérrez J.A. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 2000, 6:102-111.
85. Li M., Ransohoff R.M. The roles of chemokine CXCL12 in embryonic and brain tumor angiogenesis. Semin Cancer Biol 2009, 19:111-115.
86. Oh J.W., Drabik K., Kutsch O., Choi C., Tousson A., Benveniste E.N. CXC chemokine receptor 4 expression and function in human astroglioma cells. J Immunol 2001, 166:2695-2704.
87. Liu C., Luo D., Streit W.J., Harrison J.K. CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes. J Neuroimmunol 2008, 198:98-105.
88. Leung S.Y., Wong M.P., Chung L.P., Chan A.S., Yuen S.T. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 1997, 93:518-527.
89. Loh J.K., Lieu A.S., Su Y.F., Cheng C.Y., Tsai T.H., Lin C.L., et al. The alteration of plasma TGF-β1 levels in patients with brain tumors after tumor removal. Kaohsiung J Med Sci 2012, 28:316-321.
90. Loh J.K., Lieu A.S., Su Y.F., Cheng C.Y., Tsai T.H., Lin C.L., et al. Plasma levels of transforming growth factor-beta 1 before and after removal of low- and high-grade astrocytomas. Cytokine 2013, 61:413-418.
91. Mkhoyan G.G., Ter-Pogossian Z.R., Gasparyan M.G., Dzhagatspanyan N.G., Hovhannesyan G.G. Cytokine regulation of immune response in patients with a brain tumor or injury. Neurochem J 2008, 2:318-319.
92. Gridley D.S., Loredo L.N., Slater J.D., Archambeau J.O., Bedros A.A., Andres M.L., et al. Pilot evaluation of cytokine levels in patients undergoing radiotherapy for brain tumor. Cancer Detect Prev 1998, 22:20-29.
93. Nagarajan R.P., Costello J.F. Molecular epigenetics and genetics in neuro-oncology. Neurotherapeutics 2009, 6:436-446.
94. Piperi C., Themistocleous M.S., Papavassiliou G.A., Farmaki E., Levidou G., Korkolopoulou P., et al. High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome. Mol Med 2010, 16:1-9.
95. Thon N., Kreth S., Kreth F.W. Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. Onco Targets Ther 2013, 6:1363-1372.
96. Klein O., Grignon Y., Civit T., Auque J., Marchal J.C. Methylation status of RARbeta gene promoter in low and high grade cerebral glioma. Comparison with normal tissue. Immuno-histochemical study of nuclear RARbeta expression in low and high grade cerebral glioma cells. Comparison with normal cells. 48 tumors. Neurochirurgie 2005, 51:147-154.
97. Agathanggelou A., Honorio S., Macartney D.P., Martinez A., Dallol A., Rader J., et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001, 20:1509-1518.
98. Skiriute D., Vaitkiene P., Saferis V., Asmoniene V., Skauminas K., Deltuva V.P., et al. MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma. BMC Cancer 2012, 12:218.
99. Elias A., Siegelin M.D., Steinmüller A., von Deimling A., Lass U., Korn B., et al. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin Cancer Res 2009, 15:5457-5465.
100. Kadowaki M., Yoshioka H., Kamitani H., Watanabe T., Wade P.A., Eling T.E. DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. Int J Cancer 2012, 130:267-277.
101. Bogdahn U., Hau P., Stockhammer G., Venkataramana N.K., Mahapatra A.K., Suri A., et al. Trabedersen glioma study group targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011, 13:132-142.
102. Fakhrai H., Mantil J.C., Liu L., Nicholson G.L., Murphy-Satter C.S., Ruppert J., et al. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 2006, 13:1052-1060.
103. Cristofanon S., Fulda S. ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis 2012, 3:e432.
104. Guo L., Fan L., Pang Z., Ren J., Ren Y., Li J., et al. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release 2011, 154:93-102.